PROVEN Skincare Announces International Expansion; Personalized, Adaptive, and AI-Backed Skincare Products Now Available in the European Union and the United Kingdom
19.7.2022 11:05:00 EEST | Business Wire | Press release
PROVEN, the expert in personalized skincare, today announced its international expansion into the European Union and the United Kingdom. Products are currently available to purchase. This is PROVEN’s first international expansion since it launched in Canada in July 2021. The PROVEN team made the decision to expand across the Atlantic due to the global demand for personalized skincare solutions. This expansion comes after a period of extraordinary growth for the company, which includes the launch of its first new product since 2019, the Eye Cream Duo, and having been granted a groundbreaking patent that protects PROVEN’s use of personalization in skincare.
Since its founding in 2017 and launch in 2019, PROVEN Skincare has grown rapidly to become the leading skincare personalization brand. The company has launched five products personalized to customers’ unique needs, received the 2018 MIT Artificial Intelligence Technology Award, was awarded Best Use of Technology at the 2022 Glossy Beauty Awards for its proprietary Skin Genome Project™, and reached more than $30 million in revenue in just three years.
“I am incredibly proud to bring PROVEN’s personalized, data and AI-backed products to the people of the European Union and the United Kingdom,” said PROVEN co-founder and CEO Ming S. Zhao. “Too many consumers still rely on one-size-fits-all skincare products that do not take into account their unique concerns and needs. PROVEN provides personalized, adaptive, effective skincare solutions that take into account a person's skin, life, and environment. The entire PROVEN team is thrilled to enter these new markets and provide people with skincare solutions as unique as they are.”
In order to provide personalized skincare to customers across the European Union and the United Kingdom, the PROVEN team gathered extensive environmental data about the region and executed a major tech build to incorporate it into PROVEN's existing AI. Integrating local environmental conditions into the skincare formulas is essential for effective skincare products.
PROVEN was founded in 2017 by Ming Zhao and Dr. Amy Yuan and launched in 2019. Ming was in the midst of a career in private equity, working long hours when she began to notice the quality of her skin was suffering. She embarked on a personal mission to find products to solve her problems but found that most were expensive, didn’t work consistently, and the trial and error of trying to find something that worked was time-consuming.
She brought this up with her friend Amy, who just so happened to be a Computational Physicist at Stanford, who was having her own skin challenges. Recognizing that the beauty industry lacked a brand that offered personalized and effective solutions, the two joined forces to create a holistic, personalized approach to skincare that is completely backed by data. The result was PROVEN, which harnesses the power of big data and AI to create personalized skincare products.
PROVEN creates simple, personalized, and clinically proven skincare products at scale thanks to its proprietary Skin Genome Project™ — the largest beauty database on earth. The Skin Genome Project™ takes the following data into account in order to craft personalized products for consumers:
- The effectiveness of over 20,238 skincare ingredients.
- Information about over 100,000 individual products (luxury, prescription, generic, etc.).
- Over 20 million testimonials from real people.
- Over 4,000 scientific publications.
- The water hardness, humidity level, and UV index where you live.
PROVEN currently offers five products personalized to customers’ unique needs. The products include Personalized Cleaner, Personalized Day Moisturizer, Personalized Night Cream, Personalized Day Eye Cream, and Personalized Night Eye Cream. The products can be conveniently purchased as systems or purchased separately.
PROVEN has only been available in the United States and Canada until this expansion.
About PROVEN
PROVEN is a technology company that harnesses the power of big data and AI to create personalized skincare products. At PROVEN we are building a global self-care movement based on technology and personalization. Through our proprietary Skin Genome Project™ — the largest beauty database on earth — we’ve analyzed over 25 million consumer testimonials and 4,000 skin-related scientific papers to create simple, personalized, and clinically-proven skincare products. PROVEN is a Y Combinator alum and 2018 MIT AI Technology Award recipient. Learn more at www.provenskincare.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005333/en/
Contact information
J. Halpin
press@provenskincare.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom